Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
|
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [31] SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Tarasova, G.
    Belov, B.
    Cherkasova, M.
    Aseeva, E.
    Reshetnyak, T.
    Kosheleva, N.
    Popkova, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1180 - 1180
  • [32] PHARMACOECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CANADIAN ADULTS
    Chuck, A.
    Waye, A.
    Zanotti, G.
    Jacobs, P.
    Kellner, J.
    Tyrrell, G.
    VALUE IN HEALTH, 2012, 15 (04) : A243 - A243
  • [33] Cardiovascular, Neurological, and Immunological Adverse Events and the 23-Valent Pneumococcal Polysaccharide Vaccine
    Yoon, Dongwon
    Jeon, Ha-Lim
    Kim, Ju Hwan
    Lee, Hyesung
    Shin, Ju-Young
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352597
  • [34] The cost-effectiveness of 23-valent pneumococcal vaccine in Catalonia, Spain
    Plans-Rubió, P
    VALUE IN HEALTH, 2003, 6 (06) : 754 - 754
  • [35] A SISTEMATIC REVIEW OF THE COST-EFFECTIVENESS OF VACCINATING ELDERLY WITH THE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23)
    Nishikawa, A. M.
    Mainardi, G. M.
    Novaes, H. M.
    Sartori, A. M.
    De Soarez, P. C.
    VALUE IN HEALTH, 2017, 20 (09) : A932 - A932
  • [36] A COST-EFFECTIVENESS ANALYSIS OF VACCINATING THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN GERMANY
    Jiang, Y.
    Gauthier, A.
    Annemans, L.
    van der Linden, M.
    Nicolas-Spony, L.
    Bresse, X.
    VALUE IN HEALTH, 2011, 14 (07) : A279 - A279
  • [37] THE COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) IN TAIWAN
    Wu, D. B. C.
    Chang, C. J.
    Chien, L.
    Fang, H. C. H.
    Roberts, C. S.
    VALUE IN HEALTH, 2012, 15 (07) : A602 - A602
  • [38] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [39] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Jansen, Kathrin U.
    Jayawardene, Deepthi
    Devlin, Carmel
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3577 - 3584
  • [40] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
12345